Literature DB >> 14593973

Memantine for dementia?

.   

Abstract

Memantine (Ebixa--Lundbeck Ltd), an oral medicine, is available in the UK for treating "patients with moderately severe to severe Alzheimer's disease". It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. The company has claimed that, with memantine therapy, "improvements in activities of daily living help patients to maintain a degree of independence and be easier to care for, potentially avoiding the need for nursing home care". We assess the efficacy of memantine for dementia and discuss its place in the management of patients with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593973

Source DB:  PubMed          Journal:  Drug Ther Bull        ISSN: 0012-6543


  2 in total

Review 1.  Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease.

Authors:  T Heinen-Kammerer; H Rulhoff; S Nelles; R Rychlik
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  Different conclusions about memantine.

Authors:  Joel Lexchin
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.